Weekly Growth Hormone Wins FDA Approval for Turner Syndrome as Girls Grew Less Than on Daily Shots
The FDA approved Novo Nordisk's once-weekly growth hormone Sogroya (somapacitan-beco) for children aged 2.5 years and older with growth failure from Turner syndrome, Novo announced Friday, Nov. 20. In the single trial behind the approval, 68 girls on weekly Sogroya grew 8.9 cm (3.5 in)…